Segmentation of Low-Grade Brain Tumors Using Mutual Attention Multimodal MRI.

Early detection and precise characterization of brain tumors play a crucial role in improving patient outcomes and extending survival rates. Among neuroimaging modalities, magnetic resonance imaging (MRI) is the gold standard for brain tumor diagnostics due to its ability to produce high-contrast images across a variety of sequences, each highlighting distinct tissue characteristics. This study focuses on enabling multimodal MRI sequences to advance the automatic segmentation of low-grade astrocytomas, a challenging task due to their diffuse and irregular growth patterns.

Clinicopathological Parameters and Immunohistochemical Profiles in Correlation with MRI Characteristics in Glioblastomas.

Glioblastoma is considered the most aggressive tumor of the central nervous system. The tumor microenvironment includes several components, such as endothelial cells, immune cells, and extracellular matrix components like matrix metalloproteinase-9 (MMP-9), which facilitates the proliferation of endothelial cells with pro-angiogenic roles. The MRI characteristics of glioblastomas can contribute to determining the prognosis.

[A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model].

Unlabelled: The development of new drugs in nuclear medicine for diagnosis or treatment (chemotherapy) of brain tumors, in particular gliomas, is inextricably linked with the use of tumor models in animals (usually rats).

Objective: To compare the widely used glioma cell model C6 and the new experimental tissue model of glioblastoma 101.8.

Neuroplasticity in glioblastoma: there is more to plasticity than just low grade glioma.

Neuroplasticity is well established in low grade glioma patients. Less is known about functional plasticity in glioblastomas. A 56-year-old lady presented with a recurrent speech deficit seventeen months after her initial craniotomy for a language eloquent glioblastoma (GBM).

Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosis.

Background: Isocitrate dehydrogenase-mutant astrocytoma without cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion typically follows a slow clinical course. However, some cases show early progression on magnetic resonance imaging, and these characteristics remain under-reported. This study aimed to elucidate the characteristics of isocitrate dehydrogenase-mutant astrocytoma showing early progression on magnetic resonance imaging.

Predicting glioblastoma progression using MR diffusion tensor imaging: A systematic review.

Background And Purpose: Despite multimodal treatment of glioblastoma (GBM), recurrence beyond the initial tumor volume is inevitable. Moreover, conventional MRI has shortcomings that hinder the early detection of occult white matter tract infiltration by tumor, but diffusion tensor imaging (DTI) is a sensitive probe for assessing microstructural changes, facilitating the identification of progression before standard imaging. This sensitivity makes DTI a valuable tool for predicting recurrence.

Assessment of hypoxia and its dynamic evolution in glioblastoma via qBOLD MRI: a comparative study with metformin treatment.

Background: To investigate the accuracy of quantitative blood oxygen level-dependent (qBOLD) magnetic resonance imaging (MRI) in identifying hypoxia within glioblastoma and explore dynamic changes in oxygenation status of glioblastoma with and without metformin administration.

Methods: Three healthy and seven C6-bearing rats underwent 7-T qBOLD MRI. Oxygen extraction fraction (OEF) and cerebral metabolism rate of O (CMRO) were calculated from qBOLD data.

Towards integrating imaging and immunology in glioblastoma: mapping blood immune system metrics to tumor magnetic resonance image data.

Background: Glioblastoma is the most frequent and aggressive brain cancer. It is a highly immunology-driven disease as up to a third of its mass is composed of immune cells. Apart from immunology, imaging is a major research frontier.

How I do it: preoperative simulation and augmented reality assisted surgical resection of Glioblastoma in Broca's area.

Background: The emergence of virtual reality and augmented reality makes preoperative simulation and intraoperative real-time guidance possible, especially for lesions in functional areas.

Method: Preoperatively, the virtual reality technique allowed the simulation of tumor resection while visualizing the fiber tracts. During resection, we used augmented reality to localize the terminations of dorsal language pathways and strictly followed the preoperative plan to perform the surgery.

Radiosurgery for Hypothalamic Gliomas: A Case Report and Clinical Guidelines Form a Neurosurgical Center of Excellence.

Hypothalamic gliomas, though rare, present significant challenges in neuro-oncology due to their critical location and high morbidity risk. Pilocytic astrocytoma is the most common subtype, requiring a delicate balance between tumor control and preservation of neurological function. This study explores radiosurgery as a viable treatment option for hypothalamic gliomas, with a focus on low-grade lesions.

Towards a Risk-Based Follow-Up Surveillance Imaging Schedule for Children and Adolescents with Low-Grade Glioma.

The frequency and duration of imaging surveillance in children and adolescents with pediatric low-grade gliomas (pLGGs) aims for the early detection of recurrence or progression. Although surveillance of pLGGs is performed routinely, it is not yet standardized. The aim of the current review is to provide a comprehensive synthesis of published studies regarding the optimal frequency, intervals, and duration of surveillance.

1H-MRS parameters in non-enhancing peritumoral regions can predict the recurrence of glioblastoma.

This study aimed to evaluate the predictive value of metabolic parameters in preoperative non-enhancing peritumoral regions (NEPTRs) for glioblastoma recurrence, using multivoxel hydrogen proton magnetic resonance spectroscopy (1H-MRS). Clinical and imaging data from patients with recurrent glioblastoma were analyzed. Through co-registration of preoperative and post-recurrence MRI, we identified future tumor recurrence regions (FTRRs) and future non-tumor recurrence regions (FNTRRs) within the NEPTRs.

Atypical Presentation of Glioblastoma: A Case Report.

This case report describes a patient who presented with devastating stroke-like symptoms secondary to a cystic brain lesion that was confirmed to be glioblastoma without significant symptomatology before her dramatic presentation. It further highlights the aggressive nature and the swift growth of the tumor in a short period of time. A 55-year-old female with no significant past medical history presented to the emergency department in a comatose state.

Altering fractionation during radiation overcomes radio-resistance in patient-derived glioblastoma cells assessed using a novel longitudinal radiation cytotoxicity assay.

Purpose: Current radiotherapy (RT) in glioblastoma (GBM) is delivered as constant dose fractions (CDF), which do not account for intratumoral-heterogeneity and radio-selection in GBM. These factors contribute to differential treatment response complicating the therapeutic efficacy of this principle. Our study aims to investigate an alternative dosing strategy to overcome radio-resistance using a novel longitudinal radiation cytotoxicity assay.

Nanoparticles (NPs)-meditated si-lncRNA NONHSAT159592.1 inhibits glioblastoma progression and invasion through targeting the ITGA3/FAK/PI3K/AKT pathway.

The study aims to investigate the regulatory role of NPs lncRNA NONHSAT159592.1 in glioblastoma cells and its molecular mechanism. We have designed a reduction-responsive nanoparticle (NP) platform for efficient delivery of si-lncRNA (si-lnc).

Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.

Background: Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 on glioblastoma cells but not on healthy brain tissue. Nanobody-based (nano)CARs are gaining increasing attention as promising alternatives to classical single-chain variable fragment-based (scFv)CARs, because of their single-domain nature and low immunogenicity.